All Genomics & Sequencing articles – Page 3
-
NewsNew AI model links genetic mutations to specific diseases
Scientists have developed a new artificial intelligence tool that can identify harmful genetic mutations and predict the types of diseases they are likely to cause, offering faster diagnosis and new opportunities for drug discovery.
-
ArticleThe future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.
-
NewsAutomated lung organoids to speed up new drug development
Scientists have developed an automated method to grow lung organoids, with the hope of speeding up drug testing, reducing reliance on animal models and helping to develop new personalised treatments.
-
NewsNew mRNA therapy targets drug-resistant pneumonia
A new mRNA therapy that prompts the body to produce bacteria-killing ‘peptibodies’ has shown early success in preclinical models, offering a potential new tool in the fight against antibiotic-resistant pneumonia.
-
ArticleMapping the genome in 3D to reveal new drug targets
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
-
NewsOTULIN enzyme found to control tau production in Alzheimer’s
New research has shown that the enzyme OTULIN regulates tau at the gene-expression level rather than through protein degradation.
-
ArticleMapping lipid pockets to drug the undruggable proteome
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.
-
NewsBlood stem cell and islet cell transplant combo reverses type 1 diabetes
Stanford researchers have cured Type 1 diabetes in mice using a combination of blood stem cell and pancreatic islet cell transplants.
-
ArticleAdvancing disease biomarker research with EV multiplex profiling
Vanitha Margan, Global Product Manager for Bio-Plex Multiplex Immunoassays at Bio-Rad Laboratories, reveals how multiplexing is being used to realise the full potential of extracellular vesicles in disease monitoring.
-
NewsBacterial traces discovered within gliomas and brain metastases
Scientists have discovered active bacterial traces inside brain tumours, overturning assumptions about the brain’s sterility and opening up new possibilities for understanding – and potentially treating – gliomas and brain metastases.
-
ArticleRVX-001: a universal vaccine to tackle antimicrobial resistance
Drug-resistant infections are on the rise, endangering global health. Neil Murray from ReNewVax explains how the company’s universal pneumococcal vaccine, RVX-001, could reduce antibiotic use and help curb antimicrobial resistance.
-
ArticleDeep data not big data
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
-
ArticleAI and the future of biomarker analysis in early R&D
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.
-
ArticleWhy first-void urine could potentially change the future of HPV screening
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
-
ArticleBeyond weight loss: the gap in current drug development for obesity
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
-
NewsAlzheimer’s may disrupt fat tissue and raise metabolic disease risk
Researchers have discovered that Alzheimer’s may disrupt communication between nerves and blood vessels in fat tissue which could explain why people with Alzheimer’s are often diagnosed with heart disease and metabolic problems.
-
ArticleInside ELRIG Drug Discovery 2025: automation, AI and human-relevant models
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
-
ReportLab Automation: Where Discovery Scales
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
-
NewsTRF1 protein identified as potential obesity drug target
Researchers have discovered that removing a telomere-protecting protein, TRF1, makes mice leaner and metabolically healthier without shortening their telomeres, potentially leading to new methods for tackling obesity and age-related diseases.
-
NewsHow AI and cell data combine to make drug discovery faster
Cellarity has published a new paper in detailing an AI-powered framework that integrates single-cell transcriptomics to make drug discovery faster and more successful.